Cargando…

The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases.

CA15.3 preoperatory serum levels have been determined in 667 patients with primary untreated breast cancer and in 193 controls. The relationships between CA15.3 and several clinical and pathological parameters were evaluated. CA15.3 levels showed a highly significant direct relationship with stage,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gion, M., Mione, R., Nascimben, O., Valsecchi, M., Gatti, C., Leon, A., Bruscagnin, G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1991
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972400/
https://www.ncbi.nlm.nih.gov/pubmed/2039707
_version_ 1782135020176015360
author Gion, M.
Mione, R.
Nascimben, O.
Valsecchi, M.
Gatti, C.
Leon, A.
Bruscagnin, G.
author_facet Gion, M.
Mione, R.
Nascimben, O.
Valsecchi, M.
Gatti, C.
Leon, A.
Bruscagnin, G.
author_sort Gion, M.
collection PubMed
description CA15.3 preoperatory serum levels have been determined in 667 patients with primary untreated breast cancer and in 193 controls. The relationships between CA15.3 and several clinical and pathological parameters were evaluated. CA15.3 levels showed a highly significant direct relationship with stage, T, pT, N and the number of positive lymph nodes. The close relationship between CA15.3 and the number of positive lymph nodes was also demonstrated in a subgroup of 406 patients in which more than ten lymph nodes had been examined. CA15.3 levels were correlated with tumour size in patients without axillary metastasis as well as with the number of positive lymph nodes in pT1 tumours. CA15.3 was significantly higher in medullary than in ductal carcinoma. No relationships were found between serum CA15.3 and receptor status. We conclude from the present findings that CA15.3 in primary untreated breast cancer is a marker of tumour burden as well as of the tendency of local invasiveness (relationship between CA15.3 and nodal status in pT1 tumours).
format Text
id pubmed-1972400
institution National Center for Biotechnology Information
language English
publishDate 1991
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19724002009-09-10 The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases. Gion, M. Mione, R. Nascimben, O. Valsecchi, M. Gatti, C. Leon, A. Bruscagnin, G. Br J Cancer Research Article CA15.3 preoperatory serum levels have been determined in 667 patients with primary untreated breast cancer and in 193 controls. The relationships between CA15.3 and several clinical and pathological parameters were evaluated. CA15.3 levels showed a highly significant direct relationship with stage, T, pT, N and the number of positive lymph nodes. The close relationship between CA15.3 and the number of positive lymph nodes was also demonstrated in a subgroup of 406 patients in which more than ten lymph nodes had been examined. CA15.3 levels were correlated with tumour size in patients without axillary metastasis as well as with the number of positive lymph nodes in pT1 tumours. CA15.3 was significantly higher in medullary than in ductal carcinoma. No relationships were found between serum CA15.3 and receptor status. We conclude from the present findings that CA15.3 in primary untreated breast cancer is a marker of tumour burden as well as of the tendency of local invasiveness (relationship between CA15.3 and nodal status in pT1 tumours). Nature Publishing Group 1991-05 /pmc/articles/PMC1972400/ /pubmed/2039707 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Gion, M.
Mione, R.
Nascimben, O.
Valsecchi, M.
Gatti, C.
Leon, A.
Bruscagnin, G.
The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases.
title The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases.
title_full The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases.
title_fullStr The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases.
title_full_unstemmed The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases.
title_short The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases.
title_sort tumour associated antigen ca15.3 in primary breast cancer. evaluation of 667 cases.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972400/
https://www.ncbi.nlm.nih.gov/pubmed/2039707
work_keys_str_mv AT gionm thetumourassociatedantigenca153inprimarybreastcancerevaluationof667cases
AT mioner thetumourassociatedantigenca153inprimarybreastcancerevaluationof667cases
AT nascimbeno thetumourassociatedantigenca153inprimarybreastcancerevaluationof667cases
AT valsecchim thetumourassociatedantigenca153inprimarybreastcancerevaluationof667cases
AT gattic thetumourassociatedantigenca153inprimarybreastcancerevaluationof667cases
AT leona thetumourassociatedantigenca153inprimarybreastcancerevaluationof667cases
AT bruscagning thetumourassociatedantigenca153inprimarybreastcancerevaluationof667cases
AT gionm tumourassociatedantigenca153inprimarybreastcancerevaluationof667cases
AT mioner tumourassociatedantigenca153inprimarybreastcancerevaluationof667cases
AT nascimbeno tumourassociatedantigenca153inprimarybreastcancerevaluationof667cases
AT valsecchim tumourassociatedantigenca153inprimarybreastcancerevaluationof667cases
AT gattic tumourassociatedantigenca153inprimarybreastcancerevaluationof667cases
AT leona tumourassociatedantigenca153inprimarybreastcancerevaluationof667cases
AT bruscagning tumourassociatedantigenca153inprimarybreastcancerevaluationof667cases